Compliance Radar

Who was sanctioned, and for what?

Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.

Bribery and corruption Chemicals and pharmaceuticals Takeda Pharmaceuticals U.S.A., Inc. Clear all filters

1case from 1 jurisdiction

€11.7mTotal of monetary amounts

€11.7mLargest single case: Takeda Pharmaceuticals U.S.A., Inc.

€11.7mMedian per case with an amount

Click a bar to drill down one level.

by amount by number of cases

Where?

by region

All jurisdictions

USA €11.7m 100 % · 1 case

What for?

by topic

Gifts, hospitality and benefits €11.7m 100 % · 1 case

Who?

by company

When?

per quarter, by date of decision

Trend
Period	Cases	Total
Q3 2023	0	—
Q4 2023	0	—
Q1 2024	0	—
Q2 2024	0	—
Q3 2024	0	—
Q4 2024	0	—
Q1 2025	0	—
Q2 2025	0	—
Q3 2025	0	—
Q4 2025	0	—
Q1 2026	0	—
Q2 2026	1	€11.7m
Q3 2026	0	—

1 case

Newest first Highest amounts

14 May 2026 Takeda Pharmaceuticals U.S.A., Inc.Takeda: 13.7 million USD – speaker fees and luxury meals for prescribing physicians USAGifts, hospitality and benefits €11.7m

From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.

What organisations can take from it

Speaker programmes need a demonstrable educational purpose – repeated attendance and expensive hospitality turn them into inducements.

Relevance to training and awareness

Invitations, hospitality and fees for healthcare professionals

Authority / court: U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California
Area of law: Bribery and corruption · Gifts, hospitality and benefits
Legal basis: Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action: Other
Status of proceedings: final
Sector: Chemicals and pharmaceuticals
Employees: 10,000 or more

Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.

Sources

DOJ: Takeda Agrees to Pay $13.6M to Resolve False Claims Allegations Relating to Improper Payments (14.05.2026) Press release of an authority
HHS-OIG Enforcement Actions: Takeda Agrees to Pay $13.6M … Improper Payments to Physicians (14.05.2026) Enforcement database of an authority

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

How the radar is compiled

Official sources only

Every case is based on a decision, press release or database of an authority or a court. Press and law-firm reports count at most as additional references.

Four-eyes check

Whoever enters a case may not approve it. A second, independent check compares company, date, amount and area of law with the source. Only then is the case published.

Comparable amounts

Amounts are converted at the ECB reference rate on the day of the decision. Each case also shows the original amount.

Corrections on record

A correction is a new version that is checked again. Every change is logged. You can report errors directly on each case.

Case texts are translated from the German original. Where a translation is not yet available, the German text is shown and marked “(German original)”. Names of authorities, laws and companies are given as in the source.

The radar reports on published decisions and is not legal advice. Decisions that are not yet final are marked as such where the status is known.

Embed the radar on your website

Who was sanctioned, and for what?

Ready for training that sticks?